Skip to content
Pharma Observatory a Scientist.com platform

Organization (Industry)

Lifetech Scientific (China)

ClinicalTrials.gov lists Lifetech Scientific (China) as lead sponsor of 44 trials.

CN Industry Manufacturer
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

9 0 2012 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 4 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 5 in 2026 and about 4 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 1 trial is registered to start in 2027 or later.

This page covers Lifetech Scientific (China): 44 lead-sponsored trials and 1 legal-entity registration.

Get the Lifetech Scientific (China) report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (31)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Heart Defects, Congenital 14
Heart Septal Defects, Atrial 11
Aortic Aneurysm 9
Atrial Fibrillation 9
Aortic Aneurysm, Abdominal 7

Trials by start year as sponsor or collaborator (14)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 4
2025 4
2024 6
2023 7
2022 1
2021 4
2020 2
2019 4
2018 9
2016 1

Prediction, not a registry value: median of 36 months from start to primary completion across 9 trials still running at the 2026-10-09 snapshot; registered median of 28 months across 11 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
86% hit target (n=14) 50% on time (n=10)

Journals published in (37)

Shown in this order: most published in first.

Journals published in
Journal Publications
Circulation 10
Journal of the American College of Cardiology 7
Stroke 4
European heart journal 3
Lancet (London, England) 3

US granted patents (1)

Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.

US granted patents
US patents granted Granted in the last 5 years Most recent grant
107 52 2025-11-18

FDA inspection record (1)

FDA inspection record
Latest classification Inspections
NAI 1

FDA import refusals (1)

FDA import refusals
Refused import lines Latest refusal
1 2010-08-25

Manufacturing and distribution sites (1)

Manufacturing and distribution sites
Facility Location Regulators Member organization
LIFETECH SCIENTIFIC (SHENZHEN) CO,.LTD Shenzhen Guangdong, CN FDA

Organization relationships (7)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
Iqvia Holdings Inc. Uses vendor 1
Lanzhou University Second Hospital Co sponsors trial with 1
Beijing Anzhen Hospital Co sponsors trial with 1
Guangdong Provincial People's Hospital Co sponsors trial with 1
Chinese PLA General Hospital Co sponsors trial with 1

Latest dated events (160)

Shown in this order: newest first.

Latest dated events
Date Event Source
2027-03-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-09-30 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-04 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-03-05 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-01-19 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, biomarker capability evidence, and biomarkers this organization publishes on.